LG Chem has made a significant global impact by highlighting the successes of its infertility treatment brands. On August 8, the company announced the successful conclusion of the FAME (Fertility Advancement MEeting) Global symposium in Amsterdam, Netherlands. This event drew over 130 healthcare professionals from eight countries, including Vietnam, Thailand, and Mexico, building on the momentum from the 2022 symposium in Milan, Italy.
At the symposium, experts from Asia and South America shared cutting-edge research on the Real World Evidence (RWE) of Follitrope™ (follitropin), LG Chem’s ovulation induction brand. They also offered insights into Assisted Reproductive Technologies (ART) utilizing LG Chem products, underscoring the distinctive competitive edge of the company’s infertility treatment offerings.
LG Chem showcased its extensive 30-year heritage and global achievements in fertility treatments. The company is aggressively expanding its international market presence with Follitrope™, which leads Korea’s fertility market. LG Chem is rapidly increasing its market share in Vietnam, Mexico, and Thailand, where it has become a prominent brand. To sustain global growth, the company plans to enhance its engagement with healthcare professionals through academic marketing initiatives, including medical expert advisory groups like the Global Advisory Board Meeting (ABM) and master courses such as the World Expert ART Course by LG Chem (WELG).
In addition, LG Chem outlined its strategy to broaden its focus beyond infertility to encompass comprehensive women’s healthcare. This includes developing treatments for conditions such as endometriosis and exploring new medical technologies like digital therapeutics.
Heuisul Park, Senior Vice President and head of LG Chem’s Specialty Care business, remarked, “We are committed to enhancing our academic programs to provide more effective treatment options for global healthcare professionals, thereby improving the success rates of infertility treatments. Our goal is to extend our focus to cover all aspects of women’s health, supporting female patients throughout their lives.”
Since launching Korea’s first recombinant follicle-stimulating hormone, Follitrope™, in 2006, and introducing the highly purified menotropin IVF-M HP™ in 2013 and the premature ovulation inhibitor Ganilever™ in 2015, LG Chem has offered a broad range of pharmaceutical options for various assisted reproductive techniques.
Currently, LG Chem exports and markets its infertility treatment brands in approximately 20 countries, including Thailand, Vietnam, China, and Mexico, and aims to continue expanding its global footprint.
